Publications
63
Citations
1,480
Est. group size
~5
Recurring co-author estimate
Active years
31
Publishing since 1996
Craig J. Burd's research examines how hormones and hormone-mimicking chemicals (endocrine disrupting chemicals, or EDCs, such as bisphenol A) affect the development of hormone-sensitive tissues like the mammary gland, and how these processes relate to cancer risk in breast, prostate, and skin (melanoma). His work combines mouse models, cell lines, and molecular studies of genes such as GREB1 and cyclin D1 to understand how estrogen signaling and hormone receptor activity influence tumor development and progression. This research sits at the intersection of endocrinology, developmental biology, and cancer biology.
Publication output has grown somewhat unevenly since 2017, rising to a peak in 2023, with roughly 3 papers per year on average over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- In utero Bisphenol A exposure developmentally reprograms mammary gland fibroblasts
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Abstract 4055: Estrogen receptor beta suppresses melanoma progression through modulation of melanocyte master regulator activity
Cancer Research · 2025
- Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice
Endocrine Related Cancer · 2023
- The OSUMMER lines: A series of ultraviolet‐accelerated NRAS‐mutant mouse melanoma cell lines syngeneic to C57BL/6
Pigment Cell & Melanoma Research · 2023
- Supplementary Data from Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
2023
- Data from Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
2023
- Data from Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
2023
- Supplementary Data from Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
2023
- The OSUMMER lines: a series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Functional differences drive the selection of NRAS mutants in melanoma
bioRxiv (Cold Spring Harbor Laboratory) · 2021
- GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation
Carcinogenesis · 2020
- GREB1 regulates proliferation of estrogen receptor positive breast cancer through modulation of PI3K/Akt/mTOR signaling
bioRxiv (Cold Spring Harbor Laboratory) · 2019
- <i>In utero</i> estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness
bioRxiv (Cold Spring Harbor Laboratory) · 2019
- GREB1 isoforms regulate proliferation independent of ERα co-regulator activities in breast cancer
Endocrine Related Cancer · 2018
- Varying Susceptibility of the Female Mammary Gland to In Utero Windows of BPA Exposure
Endocrinology · 2017
- bioRxiv (Cold Spring Harbor Laboratory)×6
- Endocrine Related Cancer×2
- Pigment Cell & Melanoma Research×2
- Cancer Research×2
- Clinical Immunology×1
- Adeoluwa A. Adeluola
Medicine · The Ohio State University
- Moray J. Campbell
Medicine · The Ohio State University
- Hedieh Jafari
Medicine · The Ohio State University
- Jocelyne N. Hanquier
Medicine · Indiana University
- Timothy H. Helms
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile